Hims & Hers Health and Novo Nordisk announced a collaboration regarding the development of GLP-1 weight-loss drugs.
1 report, 1 independent
Updated Jul 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Hims & Hers Health and Novo Nordisk announced a collaboration regarding the development of GLP-1 weight-loss drugs.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Hims & Hers Health
American telehealth company
Nothing else this week.
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- BMS, Eli Lilly, and Novo Nordisk are advancing GLP-1 portfolios, investing in manufacturing, and navigating regulatory approvals.
Coverage
Newest first; wire copies grouped- financialcontent.comHims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know